Scarica l'app Stockscreener
0.4706
0.08%
-0.0004
Dopo l'orario di chiusura:
2.66
2.1894
+465.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Gt Biopharma Inc Borsa (GTBP) Ultime notizie
GT Biopharma (GTBP) Expected to Announce Quarterly Earnings on Friday - Defense World
Ellis Martin Report: GT Biopharma, Inc. (NAS - marketscreener.com
Ellis Martin Report: GT Biopharma, Inc. (NASDAQ:GTBP) Advances Platform Immuno-Oncology Strategy with FDA-Cleared Solid Tumor IND; An Interview with CEO Michael Breen - ABN Newswire
GT Biopharma (GTBP) Gets FDA Green Light to Test New Cancer-Fighting Tech in Humans - Barchart.com
GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug for GTB-5550 TriKE, B7-H3-Targeted Natural Killer Cell Engager for Solid Tumors Expressing B7-H3 - marketscreener.com
GT Biopharma gets FDA IND clearance for GTB-5550 TRiKE, B7-H3-targeted NK engager for B7-H3+ solid tumors - marketscreener.com
GT Biopharma surges as FDA clears human trial for new cancer drug - TradingView
GT Biopharma Announces FDA Clearance for GTB-5550 Phase 1 Clinical Trial Targeting Solid Tumors Expressing B7-H3 - Quiver Quantitative
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 - marketscreener.com
FDA clears GTB-5550 trial for advanced prostate and other solid tumors - Stock Titan
What analysts say about GT Biopharma Inc stock2025 Top Decliners & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
GT Biopharma, Inc. (NASDAQ:GTBP) Sees Large Increase in Short Interest - Defense World
Published on: 2026-01-18 22:59:36 - baoquankhu1.vn
Hedge Fund Bets: Will GT Biopharma Inc benefit from government policy2025 Fundamental Recap & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
THE SCARCITY DOCTRINE: 5 Assets Securing the 2026 Material Cycle - The Manila Times
GT Biopharma Submits IND for Solid Tumor Immunotherapy Targeting Portion of $362 Billion Market as Cash Position Nearly Triples - Barchart.com
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape - The AI Journal
GT Biopharma submits IND application for solid tumor cancer treatment By Investing.com - Investing.com Nigeria
GT Biopharma submits IND application for solid tumor cancer treatment - Investing.com
GT Biopharma Submits IND Application for GTB-5550 to Target $362 Billion Solid Tumor Market | GTBP Stock News - Quiver Quantitative
New immune-based drug to test B7-H3 solid tumors across 7 cancers in trial - Stock Titan
EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment - Benzinga
Big Picture: Can GT Biopharma Inc stock sustain revenue growthOil Prices & Verified Momentum Stock Watchlist - Bộ Nội Vụ
RSI Check: What Wall Street predicts for GT Biopharma Inc. stock pricePortfolio Risk Report & Accurate Entry and Exit Point Alerts - Bộ Nội Vụ
Market Rankings: Will GT Biopharma Inc stock keep outperforming rivalsPortfolio Performance Report & Safe Investment Capital Preservation Plans - Bộ Nội Vụ
Is GT Biopharma Inc. stock supported by innovation pipelineEarnings Recap Summary & Fast Moving Market Watchlists - Улправда
Why GT Biopharma Inc. stock attracts high net worth investorsModel Comparison & walk-ready comfort choices - Улправда
Will GT Biopharma Inc. (OXIA) stock keep high P E multiples2025 Top Gainers & High Accuracy Investment Signals - ulpravda.ru
GT Biopharma shares advance as flagship GTB 3650 trial escalates to next dose level - MSN
Is GT Biopharma Inc. stock supported by strong cash flows2025 Momentum Check & AI Powered Market Entry Ideas - Улправда
Is GT Biopharma Inc. stock supported by strong fundamentalsJuly 2025 WrapUp & Expert-Curated Trade Recommendations - Улправда
Can GT Biopharma Inc. stock resist market sell offsJuly 2025 Trends & Consistent Profit Trading Strategies - ulpravda.ru
Dow Theory LettersGT Biopharma, Inc.Common Stock (Nasdaq:GTBP) Stock Quote - FinancialContent
How interest rate cuts could boost GT Biopharma Inc. stockJuly 2025 Recap & Stepwise Trade Signal Implementation - ulpravda.ru
Can GT Biopharma Inc. stock double in next 5 yearsTrend Reversal & Risk Adjusted Buy and Sell Alerts - Улправда
Workboat Indexes - FinancialContent
Is GT Biopharma Inc. stock attractive for retirement portfolios2026 world cup usa national team semifinals young talents build up play odds analysis analysis - Улправда
Fibonacci Retracement Aligns with Support in Ballarpur Industries LimitedReal Estate Investment Trusts & Affordable Trading Plans - bollywoodhelpline.com
Big Money Moves: Why GT Biopharma Inc stock attracts high net worth investorsBear Alert & Stepwise Trade Execution Plans - Bộ Nội Vụ
GT Biopharma Earnings Notes - Trefis
Earnings Preview: What to Expect From KLA Corporation's Report - Barchart.com
GTBP overperforms with a 10.54 increase in share price - uspostnews.com
GT Biopharma, Inc.Common Stock (NQ: GTBP - FinancialContent
Is GT Biopharma Inc. (OXIA) stock trading at attractive multiplesMomentum Trading Signals & Small Budget Trading Ideas - Bollywood Helpline
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge - GlobeNewswire
Risk Report: Why GT Biopharma Inc OXIA stock is a strong analyst pickWatch List & Advanced Swing Trade Entry Alerts - moha.gov.vn
Is GT Biopharma Inc. (OXIA) stock suitable for passive index fundsQuarterly Growth Report & Technical Entry and Exit Tips - Улправда
Can GT Biopharma Inc. (OXIA) stock sustain breakout momentumRate Cut & Daily Entry Point Alerts - Улправда
Will GT Biopharma Inc. stock deliver long term returnsCEO Change & Safe Investment Capital Preservation Plans - Улправда
Why retail investors pile into GT Biopharma Inc. stockWeekly Trade Review & Low Drawdown Investment Ideas - Улправда
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines - The Globe and Mail
Why GT Biopharma Inc. (OXIA) stock is a strong analyst pickQuarterly Earnings Summary & Consistent Income Trade Recommendations - DonanımHaber
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 - Sahm
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):